The English Edition of Calmark’s Annual Report 2020 is published
Calmark Sweden AB’s Annual Report 2020 is now available also in English
The Annual Report 2020 is available at the corporate website: https://www.calmark.se/eng/investors/reports-and-presentations
CEO Anna Söderlund comments:
"It is with great pride and humility I look back on the past year; despite the numerous changes in the outside world, Calmark has managed to grow and to accomplish a large number of difficult and complex tasks.
Undeniably, the most important are the CE marking of our first product, Neo-Bilirubin, and our first incoming orders. This demonstrates not only that we are able to develop products, but also that there is a market demand for them. During the year, a number of distributor agreements have been concluded, in the Nordic countries and the Middle East, and with Via Global Health, active in low- and middle-income countries worldwide.”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.